We are live on ! Find out more
RNLX

Renalytix plc American Depositary Shares

Delisted

RNLX was delisted on the 7th of October, 2024.

31 hedge funds and large institutions have $13.9M invested in Renalytix plc American Depositary Shares in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

11% less funds holding

Funds holding: 3531 (-4)

17% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 12

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

68% less capital invested

Capital invested by funds: $43.8M → $13.9M (-$29.9M)

97% less call options, than puts

Call options by funds: $1K | Put options by funds: $37K

Holders
31
Holders Change
-4
Holders Change %
-11.43%
% of All Funds
0.52%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
2
Increased
10
Reduced
12
Closed
6
Calls
$1K
Puts
$37K
Net Calls
-$36K
Net Calls Change
+$179K
Name Holding Trade Value Shares
Change
Change in
Stake
GGHC
1
Gilder Gagnon Howe & Co
New York
$3.82M -$6.01M -1,264,425 -45%
PCM
2
Philosophy Capital Management
California
$2.1M +$636K +133,670 +18%
GKIM
3
GW&K Investment Management
Massachusetts
$1.39M +$2.69M +566,475 New
PGM
4
Parian Global Management
New York
$970K -$302K -63,579 -14%
PA
5
Pinnacle Associates
New York
$834K +$168K +35,392 +12%
GIM
6
Granahan Investment Management
Massachusetts
$794K -$28.9K -6,080 -2%
FAM
7
Fred Alger Management
New York
$754K -$29.2K -6,136 -2%
Lazard Asset Management
8
Lazard Asset Management
New York
$615K +$411K +86,344 +52%
PCM
9
Pentwater Capital Management
Florida
$613K +$119K +25,000 +11%
GG
10
Gofen & Glossberg
Illinois
$449K
SPC
11
Slate Path Capital
New York
$429K
JP Morgan Chase
12
JP Morgan Chase
New York
$218K +$208K +43,724 +98%
Citadel Advisors
13
Citadel Advisors
Florida
$215K -$41.5K -8,728 -9%
Barclays
14
Barclays
United Kingdom
$166K
Morgan Stanley
15
Morgan Stanley
New York
$143K +$198K +41,691 +250%
Millennium Management
16
Millennium Management
New York
$63K -$323K -67,874 -72%
HA
17
Harbor Advisors
Florida
$59K
Marshall Wace
18
Marshall Wace
United Kingdom
$53K -$202K -42,565 -66%
State Street
19
State Street
Massachusetts
$51K -$894 -188 -0.9%
STA
20
Summit Trail Advisors
New York
$45K
Envestnet Asset Management
21
Envestnet Asset Management
Illinois
$42K -$1.29K -272 -2%
PAG
22
Private Advisor Group
New Jersey
$34K +$3.97K +835 +6%
Osaic Holdings
23
Osaic Holdings
Arizona
$30K +$1.09K +230 +2%
NSIM
24
North Star Investment Management
Illinois
$12K
Simplex Trading
25
Simplex Trading
Illinois
$9K -$70.2K -14,762 -79%

RNLX Hedge Fund Activity: Q2 2022 in Review

31 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Renalytix plc American Depositary Shares (RNLX) for Q2 2022, worth a combined $13.9M — down 68% from $43.8M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of RNLX and 2 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 10 added.

The largest buyer was GW&K Investment Management, opening a new position worth an estimated $2.69M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $6.01M.

  • 31 institutional investors held Renalytix plc American Depositary Shares (RNLX) as of Q2 2022, down from 35 in Q1 2022.
  • Funds reported $13.9M of Renalytix plc American Depositary Shares stock for Q2 2022, down 68% quarter-over-quarter.
  • 2 funds opened new Renalytix plc American Depositary Shares positions in Q2 2022 and 6 closed out, a net change of -4 holders.
  • The largest Renalytix plc American Depositary Shares buyer in Q2 2022 was GW&K Investment Management, an estimated $2.69M added.
  • The largest Renalytix plc American Depositary Shares seller in Q2 2022 was Gilder Gagnon Howe & Co, an estimated $6.01M sold.

Based on aggregated 13F filings for Q2 2022.